United Therapeutics (NASDAQ:UTHR) Price Target Raised to $486.00

United Therapeutics (NASDAQ:UTHR) had its price objective raised by Wells Fargo & Company from $466.00 to $486.00 in a research report released on Monday morning,Benzinga reports. The firm currently has an equal weight rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. HC Wainwright increased their target price on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. TD Cowen increased their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Finally, Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $549.91.

United Therapeutics Stock Performance

UTHR stock opened at $541.60 on Monday. The firm has a 50 day moving average price of $493.58 and a 200-day moving average price of $471.33. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $549.50. The firm has a market capitalization of $23.74 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 1.92 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.19 EPS. As a group, sell-side analysts forecast that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $489.91, for a total value of $4,654,145.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $63,688.30. The trade was a 98.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $479.51, for a total transaction of $10,788,975.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 336,820 shares of company stock worth $166,359,058 over the last quarter. Company insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

Hedge funds have recently bought and sold shares of the company. Rockefeller Capital Management L.P. boosted its position in United Therapeutics by 10.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 127 shares during the last quarter. Corient Private Wealth LLC increased its position in shares of United Therapeutics by 13.5% during the 4th quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock valued at $9,379,000 after purchasing an additional 2,289 shares during the last quarter. Rehmann Capital Advisory Group lifted its stake in shares of United Therapeutics by 9.8% in the 4th quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock worth $1,767,000 after purchasing an additional 324 shares during the period. Tobam lifted its stake in shares of United Therapeutics by 28.9% in the 4th quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock worth $4,803,000 after purchasing an additional 2,211 shares during the period. Finally, Wick Capital Partners LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth approximately $297,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Several brokerages have lifted price targets and reiterated buy/outperform views (examples cited include HC Wainwright, RBC, Cantor Fitzgerald and UBS), supporting upside expectations and helping sentiment. Analyst Coverage Summary
• Positive Sentiment: Wells Fargo published a bullish forecast for UTHR, calling for meaningful price appreciation and adding directional support to the tape. Wells Fargo Research
• Positive Sentiment: Recent quarterly results showed EPS outperformance versus consensus (EPS beat), underpinning the fundamental case even as revenue slightly missed; analysts’ upward revisions follow those results. Quarterly Results Summary
• Neutral Sentiment: Brokerage consensus remains a “Moderate Buy” — constructive but not unanimous; this keeps expectations elevated but measured. Analyst Consensus
• Neutral Sentiment: Institutional ownership is high and several funds reported increasing stakes in recent quarters, which can support liquidity and reduce volatility. Institutional Holdings
• Negative Sentiment: Insider selling: CEO Martine Rothblatt sold 9,500 shares (~$5.0M) and CFO James Edgemond sold 10,000 shares (~$5.27M) in March; large officer sales can pressure sentiment even if company says sales are routine. SEC filings: CEO sale CEO SEC Filing, CFO sale CFO SEC Filing
• Neutral Sentiment: Short-interest reports in recent feeds show data anomalies (zero reported shares / NaN changes) and are not providing a clear short-squeeze or bearish signal at this time. Short Interest Data

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.